SMMT Summit Therapeutics Inc.
USHealthcareAs of 2026-07-10 16:00
Why SMMT matters now
Summit Therapeutics Inc. (SMMT) is a US stock in Healthcare. The latest InvestLog snapshot shows $15.25 with -1.49% on the session and $11.84B in market capitalization; recent performance reads 1-month -13.25% and YTD -21.38%.
The latest financial table shown here is Q1 2026, with revenue of $0.00, net income of $-189.4M, and EPS of $-0.24. Investors can compare that operating picture with valuation signals such as P/E unavailable and FCF yield -2.7%.
InvestLog's latest related AI research is a Insider Buy note titled "Duggan Robert W buys $50.0M of SMMT". The latest indexable market news headline is "Recursion Pharmaceuticals vs. Summit Therapeutics: Which Healthcare Stock Is a Better Buy in 2026?" from Fool - Investing News.
Additional event context on this page matters because analyst consensus is Hold with a median target of $19.50; recent insider activity includes DUGGAN ROBERT W filing P-Purchase. These signals are research inputs, not a recommendation.
Valuation
P/E (TTM)
—
PEG
—
P/B
25.75
P/S
0.00
EV/EBITDA
-10.06
DCF Value
$0.24
FCF Yield
-2.7%
Div Yield
0.0%
Margins & Returns
Gross Margin
0.0%
Operating Margin
0.0%
Net Margin
0.0%
ROE
-340.6%
ROA
-214.2%
ROIC
-248.1%
Financials
| Period | Revenue | Net Income | EPS |
|---|---|---|---|
| Q1 2026 | $0.00 | $-189.4M | $-0.24 |
| Q4 2025 | $0.00 | $-219.2M | $-0.29 |
| FY 2025 | $0.00 | $-1.08B | $-1.44 |
| Q3 2025 | $0.00 | $-231.8M | $-0.31 |
Analyst Ratings
Consensus
Hold
Target (Consensus)
$19.50
Target (Median)
$19.50
Target Range
$16.00 - $23.00
Trading Activity
Insider Trades
Related Stocks
Latest News
Company Info
Sector
Healthcare
Industry
Biotechnology
Country
US
Exchange
—
Beta
-1.31
Summit Therapeutics Inc. is a biopharmaceutical firm dedicated to discovering, developing, and commercializing therapeutic solutions, primarily targeting infectious diseases across the United States and Latin America. The company's clinical development pipeline is heavily concentrated on therapies for Clostridioides difficile infection (CDI). Its flagship product candidate, ridinilazole, is an orally administered small molecule antibiotic currently advancing through Phase III clinical trials as a treatment for CDI. Beyond its lead asset, Summit Therapeutics is also progressing SMT-738, designed to combat multidrug-resistant infections, notably carbapenem-resistant Enterobacteriaceae (CRE). Additionally, its DDS-04 series represents a potential therapeutic avenue for various infections caused by the Enterobacteriaceae family of bacteria. Established in 2003, the company maintains its headquarters in Cambridge, Massachusetts.